FDA approves Abatacept for juvenile idiopathic arthritis

Article

The Food and Drug Administration (FDA) has approved Bristol Myers Squibb's Abatacept. The treatment is indicated for patients 6 and older with moderate-to-severe polyarticular juvenile idiopathic arthritis.

The Food and Drug Administration (FDA) has approved Bristol Myers Squibb's Abatacept. The treatment is indicated for patients 6 and older with moderate-to-severe polyarticular juvenile idiopathic arthritis.

A three-part study of patients ages 6 to 17 who had an inadequate response to disease-modifying anti-rheumatic drugs tested the efficacy of Abatacept. These patients all had subtypes of juvenile idiopathic arthritis.

There were improved responses during the open-label lead-in, which was followed by the randomized, placebo-controlled part of the trial. Patients treated with Abatacept had statistically significant improvement in time to occurrence of disease flare compared with patients receiving placebo, as well as significantly fewer disease flares.

These results remained consistent in the study's third part, an open-label extension.

Recent Videos
cUTI Roundtable: Discussing and diagnosing these difficult infections
Willough Jenkins, MD
Discussing health care sustainability, climate change, and WHO's One Health goal | Image credit: Provided by Shreya Doshi
Willough Jenkins, MD
Screening for and treating the metatarsus adductus foot deformity |  Image Credit: UNFO md ltd
Wendy Ripple, MD
Wendy Ripple, MD
Courtney Nelson, MD
DB-OTO improved hearing to normal in child with profound genetic deafness | Image Credit: © Marija - © Marija - stock.adobe.com.
© 2024 MJH Life Sciences

All rights reserved.